RC
FDMT icon

Rangeley Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Rangeley Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$293K Sell
31,465
-7,200
-19% -$62.7K 0.28% 74
2025
Q4 		$290K Sell
38,665
-4,000
-9% -$40.6K 0.24% 72
2025
Q3 		$371K Buy
42,665
+29,665
+228% +$177K 0.32% 64
2025
Q2 		$48.2K Buy
+13,000
New +$45.7K 0.06% 61

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rangeley Capital's FDMT Position: Q1 2026 in Review

Rangeley Capital reduced its 4D Molecular Therapeutics (FDMT) stake by 19% in Q1 2026, selling an estimated $62.7K and leaving 31,465 shares worth $293K. The position accounts for 0.28% of the portfolio, ranked #74.

Rangeley Capital first reported a position in FDMT in Q2 2025 and has held it in 4 quarters since. The position peaked at $371K in Q3 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Rangeley Capital held 31,465 shares of 4D Molecular Therapeutics worth $293K as of Q1 2026.
  • Rangeley Capital sold 7,200 4D Molecular Therapeutics shares in Q1 2026, an estimated $62.7K.
  • 4D Molecular Therapeutics made up 0.28% of Rangeley Capital's portfolio in Q1 2026, its #74 holding.
  • Rangeley Capital first reported a position in 4D Molecular Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Rangeley Capital's 4D Molecular Therapeutics position peaked at $371K in Q3 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.